<p>结合以加速药品福利管理行业的转型，彻底改变更广泛的医疗体验</p>
<p>, /PRNewswire/ -- Abarca Health 和 LucyRx 今天宣布进行战略合并，创建唯一一家现代化、独立的药品福利管理公司，具备规模、技术和业绩记录，能够可信地为任何规模的商业和政府客户提供服务。合并后，Abarca 和 LucyRx 将为美国超过 900 万名会员提供处方服务。</p>
<p>这一时机是经过深思熟虑的。药品福利管理市场正处于一个临界点，受到新的监管范式、高成本特药和 GLP-1 的持续压力，以及客户对不同类型药品福利管理关系的需求——这种关系提供更多灵活性、真正的问责制和可持续的可负担性。雇主、消费者和医疗服务提供者理应享有更好的体验。</p>
<p>&#34;利用我们合并后的规模、技术和业绩记录，我们将加速 Abarca 在 20 多年前发起的医疗革命，&#34; LucyRx 首席执行官 David Blair 说道。&#34;我们将共同提供一个值得信赖的运营基础，量身定制的客户体验，依托一流的技术，以及以患者为中心的整体护理成本节省。&#34;</p>
<p>支撑这一战略合并的是 Abarca 的 Darwin Healthcare Intelligence 平台——专为多样化和不断发展的支付方需求而构建，对于协调更好的护理、降低福利和行政成本、以及赋予客户和会员选择权至关重要。</p>
<p>&#34;LucyRx 与我们的愿景一致，旨在让每个人的医疗体验更加无缝和个性化，&#34; Abarca Health 首席执行官 Jason Borschow 说道。&#34;我们期待利用 LucyRx 的临床能力、连接的特药护理网络，以及为全国雇主和工会服务的专业知识，深化我们的服务产品，并加速进入新的市场领域。&#34;</p>
<p>持续性仍然是首要任务。客户和会员将不会经历任何中断，日常执行将继续由相同的团队、标准、响应能力和账户关系进行。两个品牌将继续存在，并在交易完成后作为 Healthcare Revolution Partners 的全资子公司运营。每家公司将继续专注于其核心市场。LucyRx 将继续发挥其在雇主和第三方管理机构服务方面的优势，而 Abarca 将继续在健康计划和政府项目中保持领先。领导层将保持不变，Blair 和 Borschow 将继续担任各自公司的首席执行官，并在交易完成后共同担任 Healthcare Revolution Partners 的联合主席。</p>
<p>Healthcare Revolution Partners 将是一个以使命为导向的志同道合组织的联盟，致力于加速处方护理的更好方式，并彻底改变更广泛的医疗体验。合并后的实体将为市场带来独特的行业领先技术、数十年的运营专业知识，以及不懈的承诺，以规模化提供更好的体验。</p>
<p>&#34;我们团结在一起，相信通过合作，我们将使医疗服务对每个人都变得无缝和个性化，&#34; Blair 和 Borschow 总结道。</p>
<p>该交易需经监管批准和惯例成交条件。各方在交易完成之前仍然独立拥有和运营，预计交易将在 2026 年第三季度完成。</p>
<p>欲了解更多信息，请访问 acceleratetherevolution.com。</p>
<p><strong>关于 Abarca Health</strong> 在 Abarca，我们看到一个医疗服务无缝且个性化的未来，我们每天都在努力使其成为我们服务的个人和组织的现实。我们从处方开始，这是医疗服务的前线。但通过利用我们更智能的技术、简单明了的商业模式，以及一个致力于创新和寻找更好方法的团队，我们正在推动更广泛的医疗革命。了解更多信息，请访问 abarcahealth.com。</p>
<p><strong>关于 LucyRx</strong> LucyRx 是一家快速扩张的独立下一代药品福利管理公司，重新定义处方护理。凭借其全国认可的临床能力和专有平台 LucyIQ™，该公司提供实时洞察，支持基于证据的临床决策、清晰的定价和来自美国认证药剂师的卓越服务。与超过 60,000 家药房合作，LucyRx 在全国服务超过 4,000 家客户。这是经过精彩重新构想的处方护理。欲了解更多信息，请访问 lucyrx.com。</p>
<p><strong>顾问</strong> 摩根士丹利 &amp; Co. LLC 担任 Abarca Health 的财务顾问。Pietrantoni Mendez &amp; Alvarez, LLC 担任首席法律顾问，Axinn Veltrop &amp; Harkrider LLP 担任 Abarca Health 的监管顾问。</p>
<p>Great Meadows Management, LLC 担任 LucyRx 的首席财务顾问。Kirkland &amp; Ellis, LLP 和 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 担任 LucyRx 的法律顾问。</p>
<p>来源 LucyRx; Abarca Health</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw"/></p>

<p>Abarca Health 和 LucyRx 宣布进行战略合并，创建一个现代化的独立药品福利管理公司（PBM），为超过 900 万会员提供服务。此次合并旨在通过利用合并后的技术和规模来应对监管变化和高药品成本。两个品牌将作为 Healthcare Revolution Partners 的子公司运营，领导层保持不变。该交易需获得监管批准，预计将在 2026 年第三季度完成</p>

<p>Combining to accelerate PBM industry transformation and revolutionize the broader healthcare experience</p>
<div class="lb-trans"><p>结合以加速药品福利管理行业的转型，彻底改变更广泛的医疗体验</p>
</div><p>, /PRNewswire/ -- Abarca Health and LucyRx today announced a strategic combination to create the only modern, independent pharmacy benefit manager with the scale, technology, and track record to credibly serve commercial and government clients of any size. Combined, Abarca and LucyRx will provide prescription services to more than 9 million members across the United States.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Abarca Health 和 LucyRx 今天宣布进行战略合并，创建唯一一家现代化、独立的药品福利管理公司，具备规模、技术和业绩记录，能够可信地为任何规模的商业和政府客户提供服务。合并后，Abarca 和 LucyRx 将为美国超过 900 万名会员提供处方服务。</p>
</div><p>The timing is intentional. The PBM market is at a breaking point shaped by a new regulatory paradigm, sustained pressure from high-cost specialty drugs and GLP-1s, and clients demanding a different kind of PBM relationship—one that delivers more flexibility, true accountability, and sustainable affordability. Employers, consumers, and healthcare providers deserve a better experience.</p>
<div class="lb-trans"><p>这一时机是经过深思熟虑的。药品福利管理市场正处于一个临界点，受到新的监管范式、高成本特药和 GLP-1 的持续压力，以及客户对不同类型药品福利管理关系的需求——这种关系提供更多灵活性、真正的问责制和可持续的可负担性。雇主、消费者和医疗服务提供者理应享有更好的体验。</p>
</div><p>&#34;Leveraging our combined scale, technology, and track record, we will accelerate the healthcare revolution Abarca started more than 20 years ago,&#34; said David Blair, Chief Executive Officer of LucyRx. &#34;Together, we will deliver a trusted operating foundation, tailored customer experiences powered by best-in-class technology, and total-cost-of-care savings anchored in putting patients first.&#34;</p>
<div class="lb-trans"><p>&#34;利用我们合并后的规模、技术和业绩记录，我们将加速 Abarca 在 20 多年前发起的医疗革命，&#34; LucyRx 首席执行官 David Blair 说道。&#34;我们将共同提供一个值得信赖的运营基础，量身定制的客户体验，依托一流的技术，以及以患者为中心的整体护理成本节省。&#34;</p>
</div><p>Underpinning the strategic combination is Abarca's Darwin Healthcare Intelligence platform – purpose built for diverse and evolving payer needs and critical for coordinating better care, lowering benefit and administrative costs, and empowering choice for clients and members.</p>
<div class="lb-trans"><p>支撑这一战略合并的是 Abarca 的 Darwin Healthcare Intelligence 平台——专为多样化和不断发展的支付方需求而构建，对于协调更好的护理、降低福利和行政成本、以及赋予客户和会员选择权至关重要。</p>
</div><p>&#34;LucyRx shares our vision of making healthcare more seamless and personalized for everyone,&#34; said Jason Borschow, Chief Executive Officer of Abarca Health. &#34;We look forward to leveraging LucyRx's clinical capabilities, Connected Specialty Care Network, and expertise serving employers and labor groups nationwide to deepen our service offerings and accelerate our entry into new market segments.&#34;</p>
<div class="lb-trans"><p>&#34;LucyRx 与我们的愿景一致，旨在让每个人的医疗体验更加无缝和个性化，&#34; Abarca Health 首席执行官 Jason Borschow 说道。&#34;我们期待利用 LucyRx 的临床能力、连接的特药护理网络，以及为全国雇主和工会服务的专业知识，深化我们的服务产品，并加速进入新的市场领域。&#34;</p>
</div><p>Continuity remains the top priority. Clients and members will experience no disruption as day-to-day execution continues with the same teams, standards, responsiveness, and account relationships continuing as they do today. Both brands will remain in place, and at closing, operate as wholly owned subsidiaries of Healthcare Revolution Partners. Each company will remain focused on its core markets. LucyRx will continue to build on its strengths serving employers and TPAs, and Abarca will continue to lead in health plans and government programs. Leadership will remain unchanged, with Blair and Borschow continuing to serve as CEOs of their respective companies and joining Healthcare Revolution Partners as Co-Chairs at closing.</p>
<div class="lb-trans"><p>持续性仍然是首要任务。客户和会员将不会经历任何中断，日常执行将继续由相同的团队、标准、响应能力和账户关系进行。两个品牌将继续存在，并在交易完成后作为 Healthcare Revolution Partners 的全资子公司运营。每家公司将继续专注于其核心市场。LucyRx 将继续发挥其在雇主和第三方管理机构服务方面的优势，而 Abarca 将继续在健康计划和政府项目中保持领先。领导层将保持不变，Blair 和 Borschow 将继续担任各自公司的首席执行官，并在交易完成后共同担任 Healthcare Revolution Partners 的联合主席。</p>
</div><p>Healthcare Revolution Partners will be a mission-led union of like-minded organizations working to accelerate a better way in prescription care and revolutionize the broader healthcare experience. The combined entity will bring to the market a unique combination of industry-leading technology, decades of operating expertise, and an unstoppable commitment to deliver a better experience at scale.</p>
<div class="lb-trans"><p>Healthcare Revolution Partners 将是一个以使命为导向的志同道合组织的联盟，致力于加速处方护理的更好方式，并彻底改变更广泛的医疗体验。合并后的实体将为市场带来独特的行业领先技术、数十年的运营专业知识，以及不懈的承诺，以规模化提供更好的体验。</p>
</div><p>&#34;We are united by the belief that, by working together, we will make healthcare seamless and personalized for everyone,&#34; concluded Blair and Borschow.</p>
<div class="lb-trans"><p>&#34;我们团结在一起，相信通过合作，我们将使医疗服务对每个人都变得无缝和个性化，&#34; Blair 和 Borschow 总结道。</p>
</div><p>The transaction is subject to regulatory approvals and customary closing conditions. The parties remain independently owned and operated until the transaction closes, which is expected in the third quarter of 2026.</p>
<div class="lb-trans"><p>该交易需经监管批准和惯例成交条件。各方在交易完成之前仍然独立拥有和运营，预计交易将在 2026 年第三季度完成。</p>
</div><p>For more information, visit acceleratetherevolution.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 acceleratetherevolution.com。</p>
</div><p><strong>About Abarca Health</strong> At Abarca, we see a future in which healthcare is seamless and personalized, and we are working every day to make it a reality for the people and organizations we serve. We are starting with prescriptions, the frontline of healthcare. But, leveraging our smarter technology, straightforward approach to business, and a team that is driven to innovate and find a better way in everything we do, we are enabling a broader healthcare revolution. Learn more at abarcahealth.com</p>
<div class="lb-trans"><p><strong>关于 Abarca Health</strong> 在 Abarca，我们看到一个医疗服务无缝且个性化的未来，我们每天都在努力使其成为我们服务的个人和组织的现实。我们从处方开始，这是医疗服务的前线。但通过利用我们更智能的技术、简单明了的商业模式，以及一个致力于创新和寻找更好方法的团队，我们正在推动更广泛的医疗革命。了解更多信息，请访问 abarcahealth.com。</p>
</div><p><strong>About LucyRx</strong> LucyRx is a fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by its nationally recognized clinical capabilities and proprietary platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based certified pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves more than 4,000 clients nationwide. This is prescription care, brilliantly reimagined. Visit lucyrx.com for more information.</p>
<div class="lb-trans"><p><strong>关于 LucyRx</strong> LucyRx 是一家快速扩张的独立下一代药品福利管理公司，重新定义处方护理。凭借其全国认可的临床能力和专有平台 LucyIQ™，该公司提供实时洞察，支持基于证据的临床决策、清晰的定价和来自美国认证药剂师的卓越服务。与超过 60,000 家药房合作，LucyRx 在全国服务超过 4,000 家客户。这是经过精彩重新构想的处方护理。欲了解更多信息，请访问 lucyrx.com。</p>
</div><p><strong>Advisors</strong> Morgan Stanley &amp; Co. LLC is serving as financial advisor to Abarca Health. Pietrantoni Mendez &amp; Alvarez, LLC is serving as lead legal counsel, and Axinn Veltrop &amp; Harkrider LLP is serving as regulatory counsel to Abarca Health.</p>
<div class="lb-trans"><p><strong>顾问</strong> 摩根士丹利 &amp; Co. LLC 担任 Abarca Health 的财务顾问。Pietrantoni Mendez &amp; Alvarez, LLC 担任首席法律顾问，Axinn Veltrop &amp; Harkrider LLP 担任 Abarca Health 的监管顾问。</p>
</div><p>Great Meadows Management, LLC is serving as lead financial advisor to LucyRx. Kirkland &amp; Ellis, LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. are serving as legal counsel to LucyRx.</p>
<div class="lb-trans"><p>Great Meadows Management, LLC 担任 LucyRx 的首席财务顾问。Kirkland &amp; Ellis, LLP 和 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 担任 LucyRx 的法律顾问。</p>
</div><p>SOURCE LucyRx; Abarca Health</p>
<div class="lb-trans"><p>来源 LucyRx; Abarca Health</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH86200&amp;Transmission_Id=202606171418PR_NEWS_USPR_____PH86200&amp;DateId=20260617"/></p>

14:18 ETAbarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale

prnewswire

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

ETAbarca Health 和 LucyRx 宣布战略合并，旨在创建唯一一个适用于商业和政府规模的现代药品福利管理公司（PBM）